Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

15 avril 2022 mis à jour par: Vincent T. Ho, MD, Dana-Farber Cancer Institute

A Phase 2 Study of Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease (GVHD) Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant.

The device used to remove the α/βT cells in this study is:

-CliniMACS® TCR α/β Reagent System

Aperçu de l'étude

Statut

Résilié

Les conditions

Intervention / Traitement

Description détaillée

Patients who receive an allogeneic (using another person as the donor) stem cell transplant (SCT) are at risk for developing graft-versus-host disease (GVHD).

The word "graft" refers to the donor blood cells that you will receive during the transplant. The word "host" refers to the person receiving the cells. GVHD is a complication of transplantation where the donor graft attacks and damages some of the participant's tissues.

GVHD may occur when the T cells (a type of white blood cell that helps protect the body from infection) from the donor react against normal tissues or organs in the body. There are two basic types of GVHD:

  • Acute GVHD often occurs early (generally first 3-6 months after SCT) may affect skin, gastrointestinal tract (stomach and intestines) and liver.
  • Chronic GVHD often occurs later (Usually after 3-6 months after SCT) and may affect many organs and significantly diminish quality of life.

To confirm the diagnosis of acute or chronic GVHD, the participant may be asked to have a biopsy (a small sample of the participant's tissue to look at under the microscope) of the skin, gut, or, rarely, the liver.

In this research study, the investigator are investigating a pre-transplant intervention aimed to prevent GVHD by processing the donor product with the Miltenyi CliniMACS TCR α/β Reagent System. The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to the participant. By selectively removing this specific type of T cells from the donor product, the investigators hope to reduce the risk for GVHD without reducing the efficacy of the transplant.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved CliniMACS α/β T cell depletion system for use in the US, but this system is approved by the European Medicines Agency (EMA) and used in Europe

Type d'étude

Interventionnel

Inscription (Réel)

2

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Dana Farber Cancer Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Diagnoses and stage at time of transplant admission:

    • Acute leukemia (AML or ALL or MPAL) in first or subsequent remission
    • Myelodysplastic syndromes (MDS) with <10% marrow blasts
    • Myeloproliferative neoplasm (MPN) with <10% marrow blasts
    • CMML with less than 10% marrow blast
    • CML accelerated phase or second or subsequent chronic phase
    • Non-Hodgkin's lymphoma in PR or CR2 or beyond
    • Hodgkin lymphoma in PR or CR2 or beyond
  • Age 18-65 years
  • Patient has a related or unrelated donor who is 8 or 9 out of 10 match at HLA A, B, C, DRB1 and DQB1, based on allele level typing.
  • Patient ECOG performance status 0-2 (Karnofsky ≥60%, see Appendix A)
  • Patient deemed to be appropriate candidate for myeloablative conditioning transplantation.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patient with active HIV infection
  • Chronic active hepatitis B infection (HepB surface Ag+ or detectable Hep B viral load)
  • Prior allogeneic hematopoietic stem cell transplantation
  • Impaired cardiac function- ejection fraction < 40%
  • Impaired pulmonary function- pretransplant FEV1, DLCO < 50%
  • Impaired renal function, based on

    --Serum creatinine > 2.0 mg/dl

  • Impaired liver function unrelated to primary disease, based on

    --ALT or AST > 3x ULN, or Total Bilirubin > 2.0mg/dl (with exception for known or suspected Gilbert's disease)

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Women who are pregnant or breast feeding. Women of child bearing potential must have a negative serum pregnancy test at study entry.
  • Participants who are receiving any other investigational agents are eligible but such agent must be discontinued before admission for HSCT, and if resumption of investigation agent is planned after HSCT, this must be approved by the study PI.
  • Participants with known active CNS disease. CNS disease that has been treated is eligible

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: TCR α/β Reagent System
  • The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.
  • CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device
The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Severe Acute GVHD-free Survival
Délai: 100 Days
Number of participants with severe acute GVHD-free survival will be assessed at 100 days post-SCT
100 Days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Grades II-IV Acute GVHD
Délai: 2 years
Grades II-IV acute GVHD will be assessed at 2 years post-SCT. Grade I GVHD is characterized as mild disease, grade II as moderate, grade III as severe, and grade IV as life-threatening. Higher grades of acute GVHD are associated with worse outcomes. Acute GVHD will be staged by assessment of clinical manifestations in the skin, gastrointestinal tract, and liver.
2 years
Number of Participants With Chronic GVHD
Délai: 2 years
Number of participants with chronic GVHD will be assessed at 2 years post-SCT.
2 years
Number of Participants With GVHD and Relapse Free Survival (GRFS)
Délai: 2 years
GRFS will be defined as alive without having experienced grade III-IV acute GVHD, moderate/severe chronic GVHD, or relapse of underlying malignancy.
2 years
Number of Participants With Immunosuppression-free Survival
Délai: 2 years
Number of participants with immunosuppression-free survival will be assessed at 2 years post-SCT.
2 years
Number of Participants With Hematologic Recovery
Délai: 2 years
Hematologic recovery will be assessed in participants at 2 years post-SCT.
2 years
Number of Participants With Immune Reconstitution
Délai: 2 years
Immune reconstitution will be assessed in participants at 2 years post-SCT.
2 years
Number of Participants With Disease Relapse
Délai: 2 years
Disease relapse will be assessed in participants at 2 years post-SCT.
2 years
Number of Participants With Transplant-related Mortality
Délai: 2 years
Participant transplant-related mortality will be assessed at 2 years post-SCT.
2 years
Number of Participants With Organ Toxicity
Délai: 2 years
Participant organ toxicity will be assessed at 2 years post-SCT.
2 years
Rates of Infections
Délai: 2 years
Participant rate of infections will be assessed at 2 years post-SCT.
2 years
Number of Participants With Relapse-free and Overall Survival
Délai: 2 years
Number of participants with relapse-free and overall survival will be assessed at 2 years post-SCT.
2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Vincent T Ho, MD, Dana-Farber Cancer Institute

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 janvier 2020

Achèvement primaire (Réel)

26 avril 2021

Achèvement de l'étude (Réel)

26 avril 2021

Dates d'inscription aux études

Première soumission

22 octobre 2018

Première soumission répondant aux critères de contrôle qualité

22 octobre 2018

Première publication (Réel)

24 octobre 2018

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 mai 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 avril 2022

Dernière vérification

1 avril 2022

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner